Enabling future improvements in cancer care with fast next-generation sequencing
(NGS) results

In these on-demand presentations from the 2022 European Lung Cancer Conference, hear from industry leaders discuss the latest status and developments on the oncology biomarker testing scene. 

Introduction from Nicola Normanno, symposium chair, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

 

Complex biomarker-driven therapy landscape in non-small cell lung cancer (NSCLC) and the latest guidelines

Federico Cappuzzo
Istituto Nazionale Tumori Regina Elena

 

Molecular pathology—meeting the challenges of a rapidly evolving biomarker landscape

James Beasley
Birmingham Women’s and Children’s NHS Foundation Trust

 

Removing barriers to enable routine NGS testing

Paul Hofman
Louis Pasteur Hospital

Audience Q&A

Moderated by Nicola Normanno

Want to learn more about the benefits of in-house NGS for your lab?

Contact us today.

 

For Research Use only. Not for use in diagnostic procedures.